MagForce AG supports NOA Winter School 2016 from December 01-02 in Münster, Germany

DGAP-Media / 02.12.2016 / 09:00

MagForce AG supports NOA Winter School 2016 from December 01-02 in Münster,
Germany

- Team of Prof. Dr. med. Walter Stummer, Director of the Department of
Neurosurgery, University of Münster, introduces nanoparticles
application technique 'NanoPaste'

- Data recently presented at SNO Annual Meeting 2016 in Arizona, USA,
indicate strong immune-stimulating potential in addition to tumor
ablation

Berlin, Germany and Nevada, USA, December 02, 2016 - MagForce AG
(Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading
medical device company in the field of nanomedicine focused on oncology,
today announced that the Company supports NOA Winter School 2016 held by
the Neuro-Oncological Working Group (Neuroonkologische Arbeitsgemeinschaft,
NOA) on December 01 and 02, 2016, in Münster, Germany, as one of the main
sponsors.

Reporting on their experiences with NanoTherm therapy, Dr. med. Johannes
Wölfer, Deputy Director of the Neurosurgical Department, Clinic and
Policlinic for Neurosurgery, University Hospital Münster and part of the
team of Prof. Dr. med. Walter Stummer, Director of the Department of
Neurosurgery at the University Hospital Münster and President of the German
Neurosurgical Society (DGNC), will hold a presentation titled "Local
Hyperthermia as an adjuvant for malignant glioma - NanoPaste and NanoTherm"
on Friday, December 02, 2016 at 3pm local time.

As winner of the EANS 2016 Best Abstract Award, the team of the University
Hospital of Münster will be introducing its new nanoparticles application
technique called 'NanoPaste' that was developed for the use with NanoTherm
thermotherapy in glioblastoma and used first in man at the Department of
Neurosurgery in Münster.

Furthermore, Dr. Dr. med. Grauer, Associate Professor and Deputy Head of
Neuro-Oncology Center at University Hospital Münster, recently presented a
poster on the "Inflammatory response after modified NanoTherm and
radiotherapy of recurrent glioblastoma" at the 21st Annual Meeting and
Education Day of the Society for Neuro-Oncology (SNO). The SNO 2016 Annual
Meeting, which, with over 2000 participants, is one of the most important
congresses for the Neuro-Oncological community worldwide was held mid-
November in Arizona, USA.

The presentation at SNO attracted great interest among the conference
attendees. Priv.-Doz. Dr. Dr. med. Oliver Grauer explained the approach of
the Münster team in more detail: "Immune therapy is currently one of the
most interesting approaches in cancer treatment. Therefore it is important
to investigate any possible immune-related effect of NanoTherm Therapy in